

Neoplasia 3



Dr. Sura Al Rawabdeh, M.D. 23-11-2022.

GENETIC LESIONS IN CANCER

- The genetic changes found in cancers vary from :
- point mutations involving single nucleotides to abnormalities large enough to produce gross changes in chromosome structure.



Driver and Passenger Mutations


- Driver mutations are mutations that alter the function of cancer genes and directly contribute to the development or progression of a given cancer.
- They are usually acquired, occasionally inherited.

passenger mutations are acquired mutations that are neutral in terms of fitness and do not affect cellular behavior.

passenger mutations are sprinkled throughout the genome.

1.Point Mutations


- Change in single nucleotide of DNA.
- Point mutations can either activate or inactivate the protein products of the affected genes depending on their precise position and consequence.




- Point mutations that convert proto-oncogenes into oncogenes generally produce a gain of-function, e.g: RAS
- Point mutations in tumor suppressor genes reduce or disable the function of the encoded protein, e.g TP53.

2.Gene Rearrangements


- Gene rearrangements may be produced by <u>chromosomal translocations or inversions</u>.
- Specific chromosomal translocations and inversions are highly associated with certain malignancies, e.g hematopoietic cells and mesenchymal neoplasms.






These rearrangements can activate proto-oncogene in two ways:

> a. Some gene rearrangements result in overexpression of proto-oncogenes by removing them from their normal regulatory elements and placing them under control of an inappropriate, highly active promoter or enhancer.






Burkitt lymphoma

Follicular lymphoma

- b. Other oncogenic gene rearrangements create fusion genes encoding novel chimeric proteins.
- E.g Philadelphia (Ph) chromosome in chronic myeloid leukemia, consisting of a balanced reciprocal translocation between chromosomes 9 and 22.



chronic myeloid leukemia

3. Deletions

Deletion of specific regions of chromosomes may result in the loss of particular tumor suppressor genes.


Examples:

- deletions involving 13q14, the site of the RB gene, are associated with retinoblastoma.
- deletion of 17p is associated with loss of TP53, arguably the most important tumor suppressor gene.

4. Gene Amplifications


- Proto-oncogenes may be converted to oncogenes by gene amplification, with consequent overexpression and hyperactivity of otherwise normal proteins.
- Two clinically important examples of amplification :
- A. NMYC gene in neuroblastoma, and the amplification is associated with poor prognosis
- **B. HER2** gene in breast cancers


Amplification of the NMYC gene in human neuroblastoma. The NMYC gene, present normally on chromosome 2p, becomes amplified and is seen either as extrachromosomal double minutes or as a chromosomally integrated homogeneous-staining region (HSR).



5. Aneuploidy

- Aneuploidy is defined as a number of chromosomes that is not a multiple of the haploid state; for humans, that is a chromosome number that is not a multiple of 23.
- Having missing or extra chromosomes







CARCINOGENESIS:A MULTISTEP PROCESS

- No single mutation is sufficient to transform a normal cell into a cancer cell.
- Carcinogenesis is thus a multistep process resulting from the accumulation of multiple genetic alterations that collectively give rise to the transformed phenotype
- During their course cancers generally become more aggressive and acquire greater malignant potential, a phenomenon referred to as <u>tumor progression</u>.

 Cancers acquire more mutations with time, making the affected cells more adept at growth, survival, invasion, metastasis, or immune evasion.

 This explain the tendency over time for cancers to become both more aggressive and less responsive to therapy.





HALLMARKS OF CANCER

- All cancers display eight fundamental changes in cell physiology, which are considered the hallmarks of cancer.
- Self-sufficiency in growth signals
- Insensitivity to growth-inhibitory signals
- Altered cellular metabolism
- Evasion of apoptosis
- Limitless replicative potential (immortality)
- Sustained angiogenesis
- Invasion and metastasis
- Evasion of immune surveillance





Fig. 6.17 Eight cancer hallmarks and two enabling factors (genomic instability and tumor-promoting inflammation). Most cancer cells acquire these properties during their development, typically due to mutations in critical genes. (From Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 144:646 2011.)

<u>1. Self-Sufficiency in Growth Signals:</u>

generally stems from gain-of-function mutations that convert proto-oncogenes to oncogenes.

Oncogenes encode proteins called oncoproteins that promote cell growth, even in the absence of normal growth-promoting signals.



- Under physiologic conditions, cell proliferation can be readily resolved into the following steps:
- I. Binding of a growth factor to its specific receptor on the cell membrane
- 2. Transient and limited activation of the growth factor receptor, which in turn activates several signaltransducing proteins on the inner leaflet of the plasma membrane
- 3. Transmission of the transduced signal across the cytosol to the nucleus by second messengers or a cascade of signal transduction molecules
- A. Induction and activation of nuclear regulatory factors that initiate and regulate DNA transcription and the biosynthesis of other cellular components that are needed for cell division, such as organelles, membrane components, and ribosomes
- 5. Entry and progression of the cell into the cell cycle, resulting ultimately in cell division

Each one of the listed steps is susceptible to corruption in cancer cells.

- 1. Growth Factors:
- Cancers may secrete their own growth factors or induce stromal cells to produce growth factors in the tumor microenvironment, e.g, many glioblastomas secrete platelet-derived growth factor (PDGF) and express the PDGF receptor.
- 2. Growth Factor Receptors:
- Many of the growth factor receptors function as oncoproteins when they are mutated or if they overexpressed, e.g overexpression involve the epidermal growth factor (EGF) receptor family in squamous cell carcinomas of the lung, glioblastomas, and epithelial tumors of the head and neck.

- **3. Downstream Signal-Transducing Proteins:**
- result from mutations in genes that encode components of signaling pathways downstream of growth factor receptors.
- Two important oncoproteins in the category of signaling molecules are RAS and ABL.

- 4. Nuclear Transcription Factors:
- Mutations in these factors result in continuous stimulation of nuclear transcription factors that drive the expression of growth-promoting genes, e.g MYC mutation.

2. Insensitivity to Growth Inhibitory Signals: Tumor Suppressor Genes

- **Remember**:
- oncogenes encode proteins that promote cell growth, the products of tumor suppressor genes apply brakes to cell proliferation.
- Disruption of tumor suppressor genes renders cells refractory to growth inhibition and mimics the growthpromoting effects of oncogenes.


I. RB: Governor of the Cell Cycle:

- RB, a key negative regulator of the cell cycle, is directly or indirectly inactivated in most human cancers.
- Approximately 60% of retinoblastomas are sporadic, while the remaining ones are familial.
- Ioss of normal RB genes predispose to:
- Retinoblastomas
- breast cancer.
- small cell cancer of the lung.
- bladder cancer.




1. Sporadic cases:

Two mutations (hits) are required to produce retinoblastoma. These involve the RB gene, which has been mapped to chromosomal locus 13q14



• In familial cases, children inherit one defective copy of the RB gene in the germ line; the other copy is normal.




Function of the RB

- The function of the RB protein is to regulate the G1/S checkpoint, the portal through which cells must pass before DNA replication commences.
- signals that promote cell cycle progression lead to the phosphorylation and inactivation of RB, while those that block cell cycle progression act by maintaining RB in an active hypophosphorylated state

eviation

State	Phase	Abbreviation	Description
Resting	Gap 0	G ₀	A phase where the cell has left the cycle and has stopped dividing.
Interphase	Gap 1	G ₁	Cells increase in size in Gap 1. The G_1 checkpoint control mechanism ensures that everything is ready for DNA synthesis.
	Synthesis	S	DNA replication occurs during this phase.
	Gap 2	G ₂	During the gap between DNA synthesis and mitosis, the cell will continue to grow. The G_2 checkpoint control mechanism ensures that everything is ready to enter the M (mitosis) phase and divide.
Cell division	Mitosis	м	Cell growth stops at this stage and cellular energy is focused on the orderly division into two daughter cells. A checkpoint in the middle of mitosis (<i>Metaphase Checkpoint</i>) ensures that the cell is ready to complete cell division



The function of the RB protein is to regulate the G1/S checkpoint, the portal through which cells must pass before DNA replication commences. Although each phase of the cell cycle circuitry is monitored carefully, the transition from G1 to S is an extremely important checkpoint in the cell cycle "clock."

In the G1 phase, diverse signals are integrated to determine whether the cell should progress through the cell cycle, or exit the cell cycle and differentiate. The RB gene product, RB, is a DNA-binding protein that serves as a point of integration for these diverse signals, which ultimately act by altering the phosphorylation state of RB.

Specifically, signals that promote cell cycle progression lead to the phosphorylation and inactivation of RB, while those that block cell cycle progression act by maintaining RB in an active hypophosphorylated state.

